Adalta Capital Management LLC Sells 2,700 Shares of Guardant Health, Inc. (NASDAQ:GH)

Adalta Capital Management LLC decreased its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 3.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 68,263 shares of the company’s stock after selling 2,700 shares during the quarter. Guardant Health comprises approximately 1.1% of Adalta Capital Management LLC’s holdings, making the stock its 21st largest position. Adalta Capital Management LLC owned about 0.06% of Guardant Health worth $2,085,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. NewEdge Advisors LLC raised its holdings in shares of Guardant Health by 13.5% during the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock worth $59,000 after acquiring an additional 230 shares during the period. Summit Investment Advisors Inc. increased its position in shares of Guardant Health by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 12,346 shares of the company’s stock worth $377,000 after purchasing an additional 391 shares during the period. Arizona State Retirement System lifted its holdings in shares of Guardant Health by 1.1% during the 4th quarter. Arizona State Retirement System now owns 35,639 shares of the company’s stock worth $1,089,000 after acquiring an additional 403 shares during the period. Jones Financial Companies Lllp grew its position in Guardant Health by 43.5% in the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock valued at $82,000 after acquiring an additional 817 shares during the last quarter. Finally, R Squared Ltd bought a new position in shares of Guardant Health in the 4th quarter valued at $26,000. Institutional investors own 92.60% of the company’s stock.

Insider Buying and Selling at Guardant Health

In other news, CEO Amirali Talasaz sold 106,784 shares of the business’s stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $49.01, for a total value of $5,233,483.84. Following the completion of the sale, the chief executive officer now owns 2,202,672 shares in the company, valued at approximately $107,952,954.72. The trade was a 4.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold 107,248 shares of company stock worth $5,254,000 over the last quarter. Insiders own 6.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. UBS Group upped their price objective on shares of Guardant Health from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, May 1st. Morgan Stanley raised their price target on shares of Guardant Health from $42.00 to $52.00 and gave the company an “overweight” rating in a research report on Thursday, March 6th. Raymond James reaffirmed an “outperform” rating and issued a $59.00 price target (up previously from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Guggenheim reissued a “buy” rating and set a $56.00 price objective on shares of Guardant Health in a report on Monday, February 24th. Finally, TD Securities upped their price objective on shares of Guardant Health from $56.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, May 1st. Twenty-one equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $52.32.

Guardant Health Stock Down 0.7%

Shares of NASDAQ GH opened at $39.97 on Wednesday. The company has a market cap of $4.95 billion, a PE ratio of -11.23 and a beta of 1.49. The firm’s 50-day moving average price is $43.74 and its 200-day moving average price is $39.88. Guardant Health, Inc. has a 52-week low of $20.14 and a 52-week high of $52.92.

Guardant Health (NASDAQ:GH) last released its earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.08. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $203.47 million during the quarter, compared to analyst estimates of $189.91 million. During the same period in the prior year, the firm posted ($0.46) EPS. The firm’s quarterly revenue was up 20.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.